|
|
 |
|
Viewing report
|
|
|
|
U.S. Sequencing Services Markets
Frost & Sullivan, Sep 2006
This research service analyzes the market for sequencing services within the United States. The key challenges and strategies, market and technology trends, competitive structure, market share analysis, and revenue forecasts are covered for the total market.
This Frost & Sullivan research service, entitled U.S. Sequencing Services Markets, provides revenue forecasts for the overall market with detailed market trends for specific applications, end-users, and technologies. Moreover, the research service provides in depth analysis of market-wide drivers, restraints, and challenge with the corresponding strategic recommendations. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: the total U.S. Sequencing Services Markets, and the markets for U.S. Chain Terminator Sequencing Services, Next Generation Sequencing Services, Sequencing Services for Public Sector, and Sequencing Services for Private Sector.
Market Sectors
Frost & Sullivan’s expert analysts thoroughly examine the following sectors in this research:
- Sequencing Services
- Key End-user Groups
- Sequencing Technology
Technologies
The following technologies are covered in this research:
- De novo whole genome sequencing, re-sequencing, single tube sequencing, FDA submission-quality sequencing, publication-quality sequencing, GC-rich sequencing, RNAi template sequencing, serial analysis of gene expression sequencing, viral vector sequencing, 16S ribosomal RNA gene sequencing, primer walking, SNP and mutation analysis, and methylation analysis
- Public sector end-users, which include academic institutions, hospitals, medical schools, and government agencies; and private sector end-users, which include pharmaceutical companies, biotechnology companies, and agricultural companies
- Chain terminator sequencing technologies and next generation sequencing technologies
Market Overview
The dynamics of the sequencing services market requires that participating companies navigate several complex factors. For example, in 2005, the breakdown between internal sequencing, whether in individual laboratories or core facilities, and sequencing outsourced to sequencing services companies was by no means balanced. The amount of sequencing reactions conducted internally outnumbered outsourced sequencing over 2.5 to 1.0.
In addition to public sector core facilities, many pharmaceutical and biotechnology companies are still maintaining their internal sequencing operations. Furthermore, a considerable amount of sequencing is conducted by organism-specific groups, disease-specific groups, SNP discovery groups, and so on, not to mention the large-scale genome sequencing centers.
Overall, the segment of customers that outsource sequencing is growing faster than the segment that conducts sequencing internally. More researchers appreciate how sequencing services companies’ efficiencies make their offering far more competitively priced. However, while numerous institutions are finding it necessary to outsource sequencing projects when their internal pipelines are full, many institutions still demand that researchers conduct all their sequencing in-house.
The Frost & Sullivan study on U.S. Sequencing Services markets provides a detailed examination of both quantitative aspects of the market and qualitative trends. This research service evaluates the sequencing services market within the United States for 2005. It identifies key challenges facing the industry and strategic recommendations to overcome such obstacles. In addition, market drivers, restraints, trends, market size and growth, and services analysis are also provided.
Revenue forecasts for the sequencing services market are determined for the period from 2006 to 2012, with the base year as 2005. The following market analyses only incorporate revenues driven by fee-for-service contract sequencing. Therefore, revenues and trends associated internal core facility sequencing, individual laboratory-based sequencing, and large-scale genome sequencing such as those projects funded by National Institutes of Health or the Department of Energy, are excluded.
Key end-user groups include academic institutions, hospitals and medical schools, government agencies, pharmaceutical companies, biotechnology companies, and agricultural companies. Whether from the public or private sector, there are several different levels of sequencing services customers. While the majority of customers’ contracts involve the sequencing of single-tube samples, projects can have high-throughput involving thousands of samples. In addition, customers’ research aims are broad, with sequencing for functional genomics analyses, protein expression studies, disease-specific investigations, and so on.
|
|
|
|
